Pathos AI raised $237 million in a Series E round at a $3 billion valuation, with Bristol Myers Squibb leading the investment. The company says it is expanding beyond oncology into neurological conditions, citing new datasets from Tempus AI and a partnership with BMS that will initially focus on Alzheimer’s. The funding highlights a continued shift toward platform-driven discovery models that promise higher hit rates by scoring clinical and biological success probabilities. Pathos’ Foundry system uses thousands of agents to analyze clinical data, genomics, specimen-derived inputs, and competitive landscapes to guide which assets to pursue. For sponsors and the broader venture market, the round reinforces that investors are funding AI-enabled drug development with large, outcome-oriented budgets—especially when commercial-scale partners are willing to underwrite program direction.